Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 512027, 7 pages
Research Article

HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer

1Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
2Department of Surgery, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

Received 2 February 2015; Revised 13 May 2015; Accepted 14 May 2015

Academic Editor: Brian Oliver

Copyright © 2015 S. Mardente et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Figure 1 supplementary: Effect of RAGE blockage on PTEN expression in CAL 62 and BC PAP cells

Cytofluorimetric analysis of CAL 62 and BC PAP cells cultured for 24 h with or without HMGB1. Where indicated cells were pre-treated with anti RAGE antibody. Histograms represent log fluorescence versus cell number, gated on cell population of a side scatter/forward scatter histogram (SS/FS). Cell number is indicated on the y axis and fluorescence intensity is represented on the x axis. Cursor B indicates cell specific fluorescence; percentages of positive cells are reported in each histogram. Aspecific fluorescence was gated with samples labelled with secondary antibodies (monoclonal anti-mouse IgG) (not shown). Representative experiment.

Figure 2 Supplementary: Cell viability in CAL 62 and BC PAP cells treated or not with HMGB1

%% of dead cells in parental CAL 62 and BC PAP cells. 10 5 parental and transfected cells were seeded into a 6 well plate. Where indicated 10 nM HMGB1 was added to the cultures. Dead cells were determined with the trypan bleu exclusion test. Data represent the mean values of 3 independent experiments (+ SD). p<0.01 versus transfectants and parental cells and <0.05 versus transfectants and transfectants treated with HMGB1.

  1. Supplementary Material